Want to see SEER full AI Analyst Report?
SEER Stock Chart & Stats
$1.97
-$0.08(-3.90%)
At close: 4:00 PM EDT
$1.97
-$0.08(-3.90%)
Day’s Range― - ―
52-Week Range$1.55 - $2.41
Previous CloseN/A
Volume521.92K
Average Volume (3M)113.15K
Market Cap
$113.95M
Enterprise Value-$49.57
Total Cash (Recent Filing)$166.67M
Total Debt (Recent Filing)$23.03M
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Aug 06, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.24
Shares Outstanding55,315,983
10 Day Avg. Volume70,395
30 Day Avg. Volume113,152
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)0.41
Price to Sales (P/S)6.52
P/FCF Ratio-2.27
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$4.00Price Target Upside103.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.05
Revenue Forecast (FY)$16.15M
Bulls Say, Bears Say
Bulls Say
Strong Cash Runway And Low LeverageA cash balance of ~$219.5M combined with very low debt (debt/equity ~0.07–0.10) gives Seer durable financial flexibility. This funding runway supports continued R&D, commercialization investments and share repurchases while reducing near-term dilution risk and enabling time to scale consumable pull-through.
Rapidly Expanding Scientific ValidationA doubling of peer‑reviewed publications year‑over‑year materially strengthens Seer’s scientific credibility. Persistent external validation lowers adoption friction for large research customers, supports long‑term platform trust, and fuels recurring demand for consumables and analytics as studies scale.
Population-scale Partnerships And Product InnovationLarge biobank collaborations and continued product launches (SP200, Proteograph One Assay, next‑gen detector) create structural demand and path to scale. These partnerships generate predictable sample volumes, accelerate consumable pull‑through and reinforce a platform moat that supports long‑term commercial growth.
Bears Say
Persistent Negative Operating And Free Cash FlowContinued negative operating and free cash flow indicates ongoing cash burn despite improvements. Reliance on cash reserves or external financing to fund operations compresses optionality, can delay break‑even timing and increases the risk that future scaling or commercialization investments are constrained if cash generation lags expectations.
Small, Volatile Revenue Base And Compressed MarginsA modest, lumpy revenue base with steep YoY declines and a compressed gross margin highlights scale sensitivity. Achieving targeted 70–75% gross margins requires much higher instrument utilization and consumable pull‑through; until scale is reached, profitability and margin sustainability remain uncertain and sensitive to volume mix.
Competitive, Legal And Governance HeadwindsLower‑priced imitators and resulting IP litigation raise customer price pressure, margin risk and ongoing legal expense. Concurrent activist shareholder proposals and takeover dialogue add governance uncertainty, potentially diverting management focus and increasing the chances of disruptive strategic outcomes over the medium term.
Seer News
SEER FAQ
What was Seer’s price range in the past 12 months?
Seer lowest stock price was $1.55 and its highest was $2.41 in the past 12 months.
What is Seer’s market cap?
Seer’s market cap is $113.95M.
When is Seer’s upcoming earnings report date?
Seer’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were Seer’s earnings last quarter?
Seer released its earnings results on May 13, 2026. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.295 by -$0.005.
Is Seer overvalued?
According to Wall Street analysts Seer’s price is currently Undervalued.
Does Seer pay dividends?
Seer does not currently pay dividends.
What is Seer’s EPS estimate?
Seer’s EPS estimate is -0.27.
How many shares outstanding does Seer have?
Seer has 55,315,983 shares outstanding.
What happened to Seer’s price movement after its last earnings report?
Seer reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.295. Following the earnings report the stock price went down -1.13%.
Which hedge fund is a major shareholder of Seer?
Currently, no hedge funds are holding shares in SEER
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Seer Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (103.05% Upside)
$4.00 (103.05% Upside)
Hedge Fund Trend
Decreased
By 15.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $12.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.34%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-21.63%
Trailing 12-Months
Company Description
Seer
null
SEER Company Deck
SEER Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced clear short-term commercial and margin headwinds (33% YoY revenue decline, compressed gross margin to 35%, negative free cash flow) with multiple strategic positives: rapidly expanding scientific validation (publications doubled YoY), major population-scale biobank partnerships (PRECISE-SG100K and others), continued product and analytics innovation (SP200, Proteograph One Assay, next-gen detector, Raviant DIA), meaningful operating expense reductions (~20% YoY), improved net loss, strong cash position ($219.5M) and active share repurchases. Management reaffirmed full-year guidance and is taking defensive IP/legal actions against imitators while adding seasoned commercial leadership to drive commercialization. Overall, the call signals durable long-term opportunity and disciplined financial management but acknowledges near-term revenue and margin pressures.View all SEER earnings summariesSEER Stock 12 Month Forecast
Average Price Target
$4.00
▲(103.05% Upside)
Technical Analysis
Inhibikase Therapeutics
―
Surrozen
―
Instil Bio
―
TScan Therapeutics
―
Cognition Therapeutics
―
Ownership Overview
13.78% Insiders
6.19% Mutual Funds
1.06% Other Institutional Investors
75.09% Public Companies and
Individual Investors